Zotiraciclib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Zotiraciclib
- DrugBank Accession Number
- DB16656
- Background
Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 372.472
Monoisotopic: 372.195011409 - Chemical Formula
- C23H24N4O
- Synonyms
- Not Available
- External IDs
- EX 45
- SB-1317 free base
- TG-02
- TG02
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UCyclin-dependent kinase 9 inhibitorHumans UTyrosine-protein kinase Fyn inhibitorHumans UTyrosine-protein kinase Lck inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Zotiraciclib citrate 3VF50SU4RZ 1204918-73-9 NWYDRHSNEATNRI-SQQVDAMQSA-N
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 40D08182TT
- CAS number
- 1204918-72-8
- InChI Key
- VXBAJLGYBMTJCY-NSCUHMNNSA-N
- InChI
- InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+
- IUPAC Name
- (16E)-14-methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.1^{2,6}.1^{8,12}]heptacosa-1(24),2,4,6(27),8,10,12(26),16,21(25),22-decaene
- SMILES
- CN1C\C=C\CCOC2=CC(=CC=C2)C2=CC=NC(NC3=CC=CC(C1)=C3)=N2
References
- General References
- Not Available
- External Links
- ChemSpider
- 20571045
- BindingDB
- 50363196
- ChEMBL
- CHEMBL1944698
- ZINC
- ZINC000068251500
- Wikipedia
- Zotiraciclib
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Acute Myeloid Leukemia / All / Blast crisis in myelogenous leukaemia / Multiple Myeloma (MM) / Myelodysplastic Syndrome 1 1 Completed Treatment Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma 1 1 Withdrawn Treatment Hepatocellular Carcinoma 1 1, 2 Completed Treatment Astrocytoma / Astroglioma / Brain Neoplasm / High Grade Glioma: Glioblastoma (GBM) / High Grade Glioma: Gliosarcoma 1 1, 2 Recruiting Treatment Brain Neoplasm / Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0438 mg/mL ALOGPS logP 5.16 ALOGPS logP 4.63 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 13.21 Chemaxon pKa (Strongest Basic) 7.36 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 50.28 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 114.03 m3·mol-1 Chemaxon Polarizability 41.27 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCyclin-dependent kinase 9
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Transcription regulatory region dna binding
- Specific Function
- Protein kinase involved in the regulation of transcription. Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), whic...
- Gene Name
- CDK9
- Uniprot ID
- P50750
- Uniprot Name
- Cyclin-dependent kinase 9
- Molecular Weight
- 42777.155 Da
References
- Lohmann B, Le Rhun E, Silginer M, Epskamp M, Weller M: Interferon-beta sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02. Oncol Lett. 2020 Apr;19(4):2649-2656. doi: 10.3892/ol.2020.11362. Epub 2020 Jan 30. [Article]
2. DetailsTyrosine-protein kinase Fyn
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Protein tyrosine kinase activity
- Specific Function
- Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remode...
- Gene Name
- FYN
- Uniprot ID
- P06241
- Uniprot Name
- Tyrosine-protein kinase Fyn
- Molecular Weight
- 60761.49 Da
References
- Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W: The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J. 2021 Mar 13;11(3):57. doi: 10.1038/s41408-021-00436-0. [Article]
3. DetailsTyrosine-protein kinase Lck
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sh2 domain binding
- Specific Function
- Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-ce...
- Gene Name
- LCK
- Uniprot ID
- P06239
- Uniprot Name
- Tyrosine-protein kinase Lck
- Molecular Weight
- 58000.15 Da
References
- Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W: The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J. 2021 Mar 13;11(3):57. doi: 10.1038/s41408-021-00436-0. [Article]
Drug created at March 24, 2021 23:15 / Updated at May 04, 2022 18:05